

Amendment to the Claims:

1. (Previously Presented) A method for treating a patient having atopic dermatitis, comprising:
administering to a patient having atopic dermatitis a therapeutically effective amount of a composition comprising a Molluscum Contagiosum viral protein (MC148P) which possesses atopic dermatitis inhibiting activity.
2. (Original) The method according to claim 1, wherein the MC148P protein is selected from the group consisting of MC148P1, MC148P2, MC148P3 and fragments, variants, analogs, and derivatives of MC148P1, MC148P2, and MC148P3 which possess atopic dermatitis inhibiting activity.
3. (Original) The method according to claim 1, wherein administering the composition includes topically applying the composition.
4. (Original) The method according to claim 1, wherein administering the composition includes injecting the composition.
5. (Original) The method according to claim 1, wherein administering the composition includes iontophoresis.
6. (Original) The method according to claim 1, wherein administering the composition includes electroporation.
7. (Original) The method according to claim 1, wherein the composition includes a dimethyl sulfoxide carrier.

8. (Original) The method according to claim 1, wherein the composition includes an azone carrier.
9. (Original) The method according to claim 1, wherein the composition includes a liposomal carrier.
10. (Original) The method according to claim 1, wherein the composition is delivered locally to an area where atopic dermatitis is believed to be present.
11. (Currently Amended) The method according to claim 1 the composition is delivered to a patient with an ~~atonic~~ atopic disease or allergic skin disorder
12. (Previously Presented) A kit for treating an inflammatory skin disease, comprising:
multiple separately packaged portions of a composition adapted for treating atopic dermatitis comprising a Molluscum Contagiosum Viral protein (MC148P) which possesses atopic dermatitis inhibiting activity.
13. (Previously Presented) The kit according to claim 12, wherein the MC148P is selected from the group consisting of MC148P1, MC148P2, MC148P3 and fragments, variants, analogs, and derivatives of MC148P1, MC148P2, and MC148P3 which possess atopic dermatitis inhibiting activity.
14. (Previously Presented) The kit according to claim 12, wherein the kit further includes instructions teaching administration of the composition to a patient having atopic dermatitis.
15. (Original) The kit according to claim 13, wherein the instructions teach locally delivering the composition to an area adjacent where atopic dermatitis is believed to be present.

16. (Original) The kit according to claim 13, wherein the instructions teach topically applying the composition.
17. (Original) The kit according to claim 13, wherein the instructions teach injecting the composition.
18. (Previously Presented) The kit according to claim 13, wherein the instructions teach administering the composition through iontophoresis or electroporation.
19. (Original) The kit according to claim 11, wherein the composition includes a dimethyl sulfoxide carrier.
20. (Original) The kit according to claim 11, wherein the composition includes an azone carrier.
21. (Canceled)